Loading patent…
AssigneeLava Therapeutics N.V.
InventorsJohannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
Estimating the term…
The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
A compound comprising at least one single-domain antibody which binds to human CD1d, wherein the single-domain antibody comprises complementarity determining regions CDR1, CDR2 and CDR3, wherein CDR1 comprises the amino acid sequence set forth in SEQ ID NO:33, CDR2 comprises the amino acid sequence set forth in SEQ ID NO:54 and CDR3 comprises the amino acid sequence set forth in SEQ ID NO:
An antibody that comprises a CDR1, CDR2 and CDR3, wherein the CDR1 has the amino acid sequence set forth in SEQ ID NO:33, the CDR2 has the amino acid sequence set forth in SEQ ID NO:54 and CDR3 has the amino acid sequence set forth in SEQ ID NO:75.
Dependencies are inferred from the claim text.